These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 12585679)

  • 1. Beta-amyloid production, aggregation, and clearance as targets for therapy in Alzheimer's disease.
    De Felice FG; Ferreira ST
    Cell Mol Neurobiol; 2002 Dec; 22(5-6):545-63. PubMed ID: 12585679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebrolysin decreases amyloid-beta production by regulating amyloid protein precursor maturation in a transgenic model of Alzheimer's disease.
    Rockenstein E; Torrance M; Mante M; Adame A; Paulino A; Rose JB; Crews L; Moessler H; Masliah E
    J Neurosci Res; 2006 May; 83(7):1252-61. PubMed ID: 16511867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent approaches targeting beta-amyloid for therapeutic intervention of Alzheimer's disease.
    Cho JE; Kim JR
    Recent Pat CNS Drug Discov; 2011 Sep; 6(3):222-33. PubMed ID: 21834780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rho-associated protein kinase 1 (ROCK1) is increased in Alzheimer's disease and ROCK1 depletion reduces amyloid-β levels in brain.
    Henderson BW; Gentry EG; Rush T; Troncoso JC; Thambisetty M; Montine TJ; Herskowitz JH
    J Neurochem; 2016 Aug; 138(4):525-31. PubMed ID: 27246255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dysregulated Metabolism of the Amyloid-β Protein and Therapeutic Approaches in Alzheimer Disease.
    Kikuchi K; Kidana K; Tatebe T; Tomita T
    J Cell Biochem; 2017 Dec; 118(12):4183-4190. PubMed ID: 28488760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of acyl-coenzyme a: cholesterol acyltransferase activity in the processing of the amyloid precursor protein.
    Puglielli L; Ellis BC; Ingano LA; Kovacs DM
    J Mol Neurosci; 2004; 24(1):93-6. PubMed ID: 15314256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo.
    Hussain I; Hawkins J; Harrison D; Hille C; Wayne G; Cutler L; Buck T; Walter D; Demont E; Howes C; Naylor A; Jeffrey P; Gonzalez MI; Dingwall C; Michel A; Redshaw S; Davis JB
    J Neurochem; 2007 Feb; 100(3):802-9. PubMed ID: 17156133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aβ promotes VDAC1 channel dephosphorylation in neuronal lipid rafts. Relevance to the mechanisms of neurotoxicity in Alzheimer's disease.
    Fernandez-Echevarria C; Díaz M; Ferrer I; Canerina-Amaro A; Marin R
    Neuroscience; 2014 Oct; 278():354-66. PubMed ID: 25168729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cromolyn Reduces Levels of the Alzheimer's Disease-Associated Amyloid β-Protein by Promoting Microglial Phagocytosis.
    Zhang C; Griciuc A; Hudry E; Wan Y; Quinti L; Ward J; Forte AM; Shen X; Ran C; Elmaleh DR; Tanzi RE
    Sci Rep; 2018 Jan; 8(1):1144. PubMed ID: 29348604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cholesterol and Alzheimer's disease].
    Kálmán J; Janka Z
    Orv Hetil; 2005 Sep; 146(37):1903-11. PubMed ID: 16255374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Function and toxicity of amyloid beta and recent therapeutic interventions targeting amyloid beta in Alzheimer's disease.
    Rajasekhar K; Chakrabarti M; Govindaraju T
    Chem Commun (Camb); 2015 Sep; 51(70):13434-50. PubMed ID: 26247608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BACE1: the beta-secretase enzyme in Alzheimer's disease.
    Vassar R
    J Mol Neurosci; 2004; 23(1-2):105-14. PubMed ID: 15126696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Alzheimer disease: cellular and molecular aspects].
    Octave JN
    Bull Mem Acad R Med Belg; 2005; 160(10-12):445-9; discussion 450-1. PubMed ID: 16768248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disease-modifying therapies in Alzheimer's disease: how far have we come?
    Hüll M; Berger M; Heneka M
    Drugs; 2006; 66(16):2075-93. PubMed ID: 17112302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Huperzine A regulates amyloid precursor protein processing via protein kinase C and mitogen-activated protein kinase pathways in neuroblastoma SK-N-SH cells over-expressing wild type human amyloid precursor protein 695.
    Peng Y; Lee DY; Jiang L; Ma Z; Schachter SC; Lemere CA
    Neuroscience; 2007 Dec; 150(2):386-95. PubMed ID: 17945434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential treatment opportunities for Alzheimer's disease through inhibition of secretases and Abeta immunization.
    Schenk D; Games D; Seubert P
    J Mol Neurosci; 2001 Oct; 17(2):259-67. PubMed ID: 11816797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Production and catabolism of amyloid peptides in Alzheimer's disease].
    Checler F
    Therapie; 2010; 65(5):409-14. PubMed ID: 21144475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Withanolide A and asiatic acid modulate multiple targets associated with amyloid-beta precursor protein processing and amyloid-beta protein clearance.
    Patil SP; Maki S; Khedkar SA; Rigby AC; Chan C
    J Nat Prod; 2010 Jul; 73(7):1196-202. PubMed ID: 20553006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Key Peptides and Proteins in Alzheimer's Disease.
    Penke B; Bogár F; Paragi G; Gera J; Fülöp L
    Curr Protein Pept Sci; 2019; 20(6):577-599. PubMed ID: 30605056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.